Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-
prognosis and low-incidence cancers, although the incidence of intrahepatic …

Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms of the bile ducts and
represents the second most common hepatic cancer after hepatocellular carcinoma; it is sub …

Background Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine
is the standard first-line chemotherapy regimen, but no robust evidence is available for …

PURPOSE Whether triplet chemotherapy is superior to doublet chemotherapy in advanced
biliary tract cancer (BTC) is unknown. METHODS In this open-label, randomized phase II-III …

Background The incidence of intrahepatic cholangiocarcinoma (iCCA) is increasing. The
aim of the study was to provide reference survival data for patients with advanced iCCA …

Biliary tract cancers (BTCs) include a heterogeneous group of highly aggressive
hepatobiliary malignancies, representing the 3% of all gastrointestinal cancers and the …

Cholangiocarcinoma (CCA) represents a disease entity that comprises a heterogeneous
group of biliary malignant neoplasms, with variable clinical presentation and severity. It may …

Biliary tract cancer accounts for< 1% of all cancers and affects chiefly an elderly population,
with predominance in men. We distinguish cholangiocarcinoma (intrahepatic, hilar and …

Most of the patients with cholangiocarcinoma (CCA) present with advanced (inoperable or
metastatic) disease, and relapse rates are high in those undergoing potentially curative …

Currently, the only curative treatment for cholangiocarcinoma (CCA) is surgical resection,
though this treatment is possible in less than 40% of patients. However, recent …